Diabetology International, published by Springer Japan KK, is a leading journal dedicated to the field of diabetes research. With an ISSN of 2190-1678 and E-ISSN of 2190-1686, this journal plays a pivotal role in disseminating innovative studies and findings that advance understanding in endocrinology, diabetes, and metabolism. Its rigorous peer-review process ensures the publication of high-quality research articles, review papers, and clinical studies, making it a valuable resource for researchers, healthcare professionals, and students. The journal is indexed in Scopus and maintains respectable rankings in its categories, standing at Q3 in Endocrinology, Diabetes and Metabolism, and Q2 in Internal Medicine as of 2023. Furthermore, the journal facilitates collaborations and promotes the exchange of ideas from its base in Tokyo, Japan, helping to bridge the gap between academia and clinical practice. As it converges through the years from 2010 to 2024, Diabetology International remains committed to addressing the evolving challenges in diabetes care and research, supporting the global community's pursuit of knowledge in this crucial field.

Diabetologie is a dedicated academic journal published by Springer Heidelberg, focusing on the diverse fields of endocrinology, diabetes, and metabolism. With the ISSN 2731-7447 and E-ISSN 2731-7455, this journal serves as a significant platform for the dissemination of innovative research and evidence-based practices within the rapidly evolving landscape of diabetes care and management. Although currently not classified as Open Access, the journal provides robust subscription options that grant access to a wealth of peer-reviewed articles, making it an invaluable resource for researchers and practitioners alike. With an H-index that reflects its emerging influence and a Scopus ranking in the 10th percentile within its category, Diabetologie aims to elevate the scientific understanding of diabetes through rigorous scholarship. The journal captures the latest findings and clinical advancements from 2022 to 2024, placing a particular emphasis on novel therapeutic strategies and technological innovations. By fostering a collaborative environment dedicated to the improvement of diabetes outcomes, Diabetologie stands as a crucial contributor to the global dialogue on diabetes treatment and research.

The Journal of Diabetology, published by Wolters Kluwer Medknow Publications, is a premier platform dedicated to advancing the understanding and management of diabetes and related metabolic disorders. Since its inception in 2010, this Open Access journal has provided researchers and healthcare professionals with a wealth of knowledge through rigorous peer-reviewed articles that cover clinical research, epidemiology, and innovative treatment strategies. With an E-ISSN of 2078-7685 and a commitment to disseminating high-quality scientific work, the journal plays a pivotal role in contributing to the global discourse on diabetes care and prevention. Its dedication to accessibility enhances its impact on both established scholars and emerging researchers seeking to make meaningful contributions in the field. By fostering a collaborative environment, the Journal of Diabetology aims to bridge the gap between research and practical implementation, ultimately improving outcomes for individuals affected by diabetes.

The British Journal of Diabetes, published by the Association of British Clinical Diabetologists, is a premier journal dedicated to advancing the understanding, prevention, and management of diabetes. With an ISSN of 2397-6233, this journal aims to disseminate high-quality research findings, clinical studies, and reviews that address the complexities of diabetes care and research. While currently not available as an open access option, the journal is committed to enhancing the visibility of cutting-edge diabetes research for healthcare professionals and academics. Located in the heart of England, this journal plays a crucial role in bridging the gap between clinical practice and research innovation, making it an essential resource for practitioners, researchers, and students alike. The British Journal of Diabetes is determined to contribute significantly to the global dialogue on diabetes, as it covers a wide spectrum of topics from epidemiology and public health to novel therapeutic strategies and patient management approaches.

Diabetes Technology & Therapeutics is a leading journal published by MARY ANN LIEBERT, INC, dedicated to advancing the field of diabetes management through innovative technologies and therapeutic strategies. With an impressive impact factor and recognized as a Q1 journal in Endocrinology, Diabetes and Metabolism, as well as Medical Laboratory Technology, it occupies a pivotal position in the academic landscape. This esteemed publication features a comprehensive range of articles that cover cutting-edge research, clinical applications, and developments in diabetes care from 1999 to 2024, making it a critical resource for researchers, health professionals, and students alike. The journal is committed to fostering dialogue between disciplines, especially given its strong rankings in various scientific categories including the 98th percentile in Medical Laboratory Technology. By opting for subscription-based access, readers gain insight into the latest innovations that are shaping diabetes technology and treatment paradigms, thereby enhancing patient outcomes and advancing the scientific community's understanding of this complex disease.

The Journal of Diabetes and Metabolic Disorders, published by SPRINGER INT PUBL AG, is a premier academic journal dedicated to advancing research in the fields of endocrinology, diabetes, and metabolism. With an E-ISSN of 2251-6581, this journal plays a crucial role in disseminating high-quality research findings from 2012 to 2024, serving as a valuable resource for researchers, practitioners, and students alike. Notably, it has achieved impressive rankings, being placed in the Q2 quartile for Internal Medicine and Q3 for Endocrinology, Diabetes, and Metabolism in 2023, reflecting its influence within the scientific community. The Journal’s commitment to open access ensures that its comprehensive articles, encompassing topics from metabolic disorders to novel therapeutic approaches, are readily available to a global audience. Position yourself at the forefront of medical advancements—contribute to and benefit from the pivotal research presented in this journal.

Primary Care Diabetes is a leading journal published by ELSEVIER SCI LTD, focusing on the intersection of diabetes care, endocrinology, and family medicine. Since its inception in 2007, the journal has made significant contributions to the field, achieving notable rankings in various categories, such as Q2 in Endocrinology, Diabetes and Metabolism, Q1 in Family Practice, and Q2 in Internal Medicine, as well as Nutrition and Dietetics for 2023. With an ISSN of 1751-9918 and an E-ISSN of 1878-0210, it serves as an essential resource for researchers, healthcare professionals, and students dedicated to advancing knowledge and practice in primary diabetes care. The journal's strong Scopus rankings reflect its commitment to publish high-quality research, fostering clinical practice improvements and enhanced patient outcomes. Although not open access, its articles are pivotal for anyone looking to stay ahead in the dynamic and vital domain of diabetes management.

Journal of Diabetes Investigation is a prestigious open-access journal published by WILEY, dedicated to advancing knowledge in the fields of Endocrinology, Diabetes, and Metabolism. With its ISSN 2040-1116 and E-ISSN 2040-1124, the journal provides a vital platform for researchers, healthcare professionals, and students to disseminate high-quality research, foster innovative ideas, and engage with cutting-edge developments in diabetes investigation. Since its inception in 2010, the journal has established a solid reputation, ranking in Q2 for Endocrinology and Diabetes and Metabolism, and Q1 for both Internal Medicine and Miscellaneous Medicine categories in 2023. Its Scopus rankings further underscore its impact, notably at the 76th percentile in Internal Medicine. The open access model, adopted in 2014, ensures that vital information is freely available, promoting global collaboration and knowledge sharing. The journal is not only a reflection of Australia's commitment to medical research but also a beacon for advancements that can ultimately enhance patient outcomes in diabetes care.

Journal of Clinical and Translational Endocrinology is a peer-reviewed open access journal published by Elsevier that has been serving the endocrinology community since its inception in 2014. With an ISSN of 2214-6237, this journal focuses on the critical intersection of clinical and translational research in endocrinology, diabetes, and metabolism, offering insights that bridge laboratory discoveries with patient care. It holds a commendable position in the field, ranking Q3 for Endocrinology and Q2 for Endocrinology, Diabetes, and Metabolism, reflecting its rigorous standards and relevance to contemporary research. Situated in the Netherlands, the journal’s aim is to foster knowledge dissemination and collaboration among professionals, researchers, and students alike, ensuring high visibility in a rapidly evolving field. The journal is committed to open access, allowing immediate access to research findings, thus maximizing their impact and facilitating advancements in clinical practice and research. With an H index that showcases its contribution to the field, Journal of Clinical and Translational Endocrinology is an essential resource for anyone invested in advancing endocrinological science.

DIABETES OBESITY & METABOLISM, published by Wiley, is a premier international journal dedicated to the fields of endocrinology, diabetes, and metabolic disorders. With an impressive impact factor and its status as a Q1 journal in multiple categories—including Endocrinology and Internal Medicine—this publication is highly regarded in the academic community. Since its inception in 1999, the journal has served as a crucial platform for the dissemination of cutting-edge research, reviews, and clinical studies, driving advancements in understanding and treatment of diabetes and obesity. Researchers and professionals alike benefit from its rigorous peer-review process and extensive reach, as it aims to bridge the gap between laboratory findings and clinical applications. Although not an Open Access journal, articles are accessible through institutional subscriptions, ensuring that vital knowledge reaches those committed to enhancing patient care and expanding the scientific body of work in these pivotal areas.